Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19.
Front Pharmacol
; 13: 799338, 2022.
Article
in English
| MEDLINE | ID: covidwho-1779956
ABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19) has led to the emergence of global health care. In this study, we aimed to explore the association between drug treatments and the incidence of drug-induced liver injury (DILI) in hospitalized patients with COVID-19. A retrospective study was conducted on 5113 COVID-19 patients in Hubei province, among which 395 incurred liver injury. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards models. The results showed that COVID-19 patients who received antibiotics (HR 1.97, 95% CI 1.55-2.51, p < 0.001), antifungal agents (HR 3.10, 95% CI 1.93-4.99, p < 0.001) and corticosteroids (HR 2.31, 95% CI 1.80-2.96, p < 0.001) had a higher risk of DILI compared to non-users. Special attention was given to the use of parenteral nutrition (HR 1.82, 95% CI 1.31-2.52, p < 0.001) and enteral nutrition (HR 2.71, 95% CI 1.98-3.71, p < 0.001), which were the risk factors for liver injury. In conclusion, this study suggests that the development of DILI in hospitalized patients with COVID-19 needs to be closely monitored, and the above-mentioned drug treatments may contribute to the risk of DILI.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Front Pharmacol
Year:
2022
Document Type:
Article
Affiliation country:
Fphar.2022.799338
Similar
MEDLINE
...
LILACS
LIS